Arslantaş Esra, Ayçiçek Ali, Özkara Selvinaz, Özkan Karagenç Ayşe, Tekgündüz Sibel Akpınar, Yıldırgan Duygu, Tahtakesen Güçer Tuba Nur, Kaçar Ayşe Gonca, Hançerli Özgü, Ertürk Saide, Paslı Uysalol Ezgi, Bayram Cengiz
Department of Pediatric Hematology and Oncology, Başakşehir Çam and Sakura City Hospital, Istanbul 34480, Turkey.
Department of Pathology, Başakşehir Çam and Sakura City Hospital, Istanbul 34480, Turkey.
Diagnostics (Basel). 2024 Dec 11;14(24):2776. doi: 10.3390/diagnostics14242776.
This study aimed to compare bone marrow aspirate (BMA) multicolor flow cytometry (MFC) analysis and bone marrow biopsy (BMB) in detecting bone marrow (BM) involvement in children with neuroblastoma (NB) at diagnosis and during follow-up.
A total of 132 BM samples from 39 patients (M/F ratio: 19/20; median age: 38 months) with neuroblastoma were simultaneously obtained for evaluation. The samples were investigated for BM involvement using BMB and MFC.
A comparison between MFC (: 60) and BMB (: 60) was possible for 120 samples. When BMB was considered as the reference standard, MFC had diagnostic sensitivity, specificity, positive predictive value, and negative predictive value of 86%, 58%, 54%, and 88%, respectively, and values of 90%, 57%, 60%, and 89%, respectively, at diagnosis. The median proportion of CD45-/CD56+ cells in MFC was 0.028% (range 0-35%). The event-free survival (EFS) rates for MFC (+) and MFC (-) patients according to the analysis results of the BM samples at the time of diagnosis were 70.6% and 81.8%, respectively ( = 0.607), and the overall survival (OS) rates were 88.2% in MFC (+) patients and 90.9% in MFC (-) patients ( = 0.583).
Multicolor flow cytometry may be used as an adjunct to cytomorphology to achieve more sensitive and accurate results as an objective, quantitative method with fast results in detecting bone marrow involvement in children with NB.
本研究旨在比较骨髓穿刺液（BMA）多色流式细胞术（MFC）分析与骨髓活检（BMB）在检测神经母细胞瘤（NB）患儿诊断时及随访期间骨髓（BM）受累情况的差异。
共获取39例神经母细胞瘤患者（男/女比例：19/20；中位年龄：38个月）的132份骨髓样本用于评估。采用BMB和MFC对样本进行骨髓受累情况检测。
120份样本可同时进行MFC（n = 60）和BMB（n = 60）比较。以BMB为参考标准时，MFC的诊断敏感性、特异性、阳性预测值和阴性预测值分别为86%、58%、54%和88%，诊断时分别为90%、57%、60%和89%。MFC中CD45-/CD56+细胞的中位比例为0.028%（范围0 - 35%）。根据诊断时骨髓样本分析结果，MFC（+）和MFC（-）患者的无事件生存率（EFS）分别为70.6%和81.8%（P = 0.607），总生存率（OS）在MFC（+）患者中为88.2%，在MFC（-）患者中为90.9%（P = 0.583）。
多色流式细胞术可作为细胞形态学的辅助手段，作为一种客观、定量且结果快速的方法，在检测NB患儿骨髓受累情况时获得更敏感、准确的结果。
